Payment overview · 2025
General Payments
$591.37
33 reported records · 14 companies
Healthcare provider profile · identity verified
Steven Neus, MD
Allopathic & Osteopathic Physicians|Family Medicine · FOSTER, KY · NPI 1801895396
Verified facts
What the public records show
CMS Open Payments records show Steven Neus, MD received $591.37 in general payments during 2025 across 33 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro, Otezla, Trelegy Ellipta, Xifaxan.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 371 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $166.14 | 28.1% | 12 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $83.45 | 14.1% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $54.93 | 9.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $53.17 | 9.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.14 | 6.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.42 | 6.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.30 | 5.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.20 | 4.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.87 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.76 | 3.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.10 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.50 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.89 | 2.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.50 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $576.52 | 32 |
| Education | $14.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $166.14 | 12 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $83.45 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $54.93 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $53.17 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.14 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
371 | 36 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 660 | 150 |
| Gabapentin | Gabapentin | 596 | 100 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 460 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 413 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 384 | 94 |
| Eliquis | Apixaban | 371 | 36 |
| Furosemide | Furosemide | 350 | 77 |
| Alprazolam | Alprazolam | 344 | 43 |
| Losartan Potassium | Losartan Potassium | 281 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 264 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 262 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 74 |
| Potassium Chloride | Potassium Chloride | 246 | 56 |
| Lisinopril | Lisinopril | 244 | 65 |
| Lorazepam | Lorazepam | 241 | 40 |
| Famotidine | Famotidine | 217 | 42 |
| Clonazepam | Clonazepam | 207 | 25 |
| Metformin Hcl | Metformin Hcl | 188 | 52 |
| Trazodone Hcl | Trazodone Hcl | 184 | 43 |
| Omeprazole | Omeprazole | 183 | 54 |
| Torsemide | Torsemide | 177 | 27 |
| Donepezil Hcl | Donepezil Hcl | 176 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 44 |
| Mirtazapine | Mirtazapine | 171 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 30 |
| Carvedilol | Carvedilol | 158 | 23 |
| Divalproex Sodium | Divalproex Sodium | 156 | suppressed |
| Levetiracetam | Levetiracetam | 156 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 46 |
| Tramadol Hcl | Tramadol Hcl | 154 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 144 | 43 |
| Memantine Hcl | Memantine Hcl | 142 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 30 |
| Sertraline Hcl | Sertraline Hcl | 133 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 37 |
| Jardiance | Empagliflozin | 126 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 26 |
| Diazepam | Diazepam | 124 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 111 | 19 |
| Xarelto | Rivaroxaban | 106 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 25 |
| Prednisone | Prednisone | 99 | 54 |
| Ozempic | Semaglutide | 93 | 15 |
| Spironolactone | Spironolactone | 90 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 89 | 16 |
| Azithromycin | Azithromycin | 88 | 56 |
| Finasteride | Finasteride | 87 | suppressed |
| Meloxicam | Meloxicam | 87 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 19 |
| Methylprednisolone | Methylprednisolone | 83 | 69 |
| Farxiga | Dapagliflozin Propanediol | 82 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 21 |
| Allopurinol | Allopurinol | 79 | 18 |
| Buspirone Hcl | Buspirone Hcl | 79 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 73 | 11 |
| Montelukast Sodium | Montelukast Sodium | 71 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 28 |
| Risperidone | Risperidone | 70 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 17 |
| Pregabalin | Pregabalin | 69 | 15 |
| Alendronate Sodium | Alendronate Sodium | 61 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 60 | 11 |
| Synthroid | Levothyroxine Sodium | 59 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 19 |
| Glimepiride | Glimepiride | 58 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 13 |
| Ezetimibe | Ezetimibe | 55 | 13 |
| Bupropion Hcl | Bupropion Hcl | 54 | suppressed |
| Olanzapine | Olanzapine | 54 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 11 |
| Nifedipine Er | Nifedipine | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 49 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 48 | suppressed |
| Cefdinir | Cefdinir | 48 | 44 |
| Fluconazole | Fluconazole | 48 | 20 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 48 | suppressed |
| Simvastatin | Simvastatin | 48 | 12 |
| Methocarbamol | Methocarbamol | 47 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 34 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 30 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 16 |
| Celecoxib | Celecoxib | 42 | 11 |
| Cephalexin | Cephalexin | 42 | 30 |
| Sevelamer Carbonate | Sevelamer Carbonate | 42 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 36 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 17 |
| Latanoprost | Latanoprost | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 15 |
| Nystatin | Nystatin | 33 | 20 |
| Testosterone | Testosterone | 33 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 15 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 24 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Dexamethasone | Dexamethasone | 29 | suppressed |
| Metronidazole | Metronidazole | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 14 |
| Gemtesa | Vibegron | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 11 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 14 |
| Penicillin V Potassium | Penicillin V Potassium | 23 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Colchicine | Colchicine | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Otezla | Apremilast | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | 11 |
| Constulose | Lactulose | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $591.37 · 33 records | Bayer Healthcare Pharmaceuticals Inc. | Auvelity, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, TRELEGY ELLIPTA, TRINTELLIX, VIVITROL, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error